PLYGF (PolyPeptide Group AG) Other Financing: $-0.9 Mil (TTM As of Dec. 2025)


PLYGF PolyPeptide Group AG PLYGF
56 GF Score
Price $43.00
GF Value $26.83
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Other Financing?

PolyPeptide Group AG PLYGF 56 Other Financing is $-0.9 Mil as of Dec. 2025. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review.

PolyPeptide Group AG's Other Financing for the six months ended in Dec. 2025 was $0.3 Mil.

PolyPeptide Group AG's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.9 Mil.

PolyPeptide Group AG Other Financing Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Other Financing Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -20.47 -0.60 -0.67 -0.73 -0.91

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.38 -0.36 -1.17 0.28
PLYGF
56GF Score
PolyPeptide Group AG PLYGF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.9 Mil mean?
PolyPeptide Group AG (PLYGF) has a Other Financing of $-0.9 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Other Financing too high?
PolyPeptide Group AG's current Other Financing is $-0.9 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Other Financing compare to ZTS and UTHR?
PolyPeptide Group AG's Other Financing of $-0.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Other Financing is $-0.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current Other Financing is $-0.9 Mil. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Other Financing is $-0.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for PLYGF:

  • Other Financing: $-0.9 Mil
  • GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score

Get the complete analysis for PLYGF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.00
Price
$26.83
GF Value